Medical News

Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) and Cardi...
Cardiovasc Diabetol.

SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of...

11 May 2021

Factors Predisposing to Survival after Resuscitation for Sud...
J Am Coll Cardiol.

In this 4-year countywide study of OHCAs, only one-third were sudden, of which one-half were resuscitated to...

11 May 2021

Antiarrhythmic Therapy and Risk of Cumulative Ventricular Ar...
Int J Cardiol.

In a large cohort of ARVC patients with a long-term follow-up, only beta-blockers administrated at >50% target...

07 May 2021

Prognosis and Management of New‐onset Atrial Fibrillation in...
BMC Cardiovasc Disord.

Critically ill patients with new-onset AF have significantly increased hospital and 90-day mortality compared with...

06 May 2021

Key Trials

Benefits of Inhaled Budesonide in Early COVID-19 Infection: STOIC Study

This infographic summarises the key points of the STOIC study and outlines the benefits of administering inhaled budesonide in early COVID-19...

The ARIC Study: Prevalence and Prognosis of Mitral Regurgitation in ADHF Patients

Patients hospitalized with ADHF are burdened with higher prevalence of MR. higher severity of MR was associated with an increased risk of 1-year...

PROVE HF: Impact of Sacubitril/valsartan on Atrial Natriuretic Peptide in Patients with HFrEF

Amongst patients with HFrEF, sacubitril/valsartan treatment improved the ANP levels. Improvement in ANP levels in turn was associated with improved...

ALLHAT Study: Worsening of Kidney Function-A Major Contributor of HF Risk in Hypertensives

Worsening of kidney function is a major contributor towards the risk of HF in patients with hypertension. Choosing an antihypertensive that would...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Rivazest (Rivaroxaban) Monograph

Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...

Telyse (Tenecteplase) Monograph

In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....

Mexiletine FAQ Booklet

Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...

Mexohar (Mexiletine) Monograph

About 5% of patients with cardiac arrhythmias or with heart failure are diagnosed with a ventricular tachycardia. Recurrent Ventricular Tachycardia...

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?

23% (6 votes)
23% (6 votes)
12% (3 votes)
12% (3 votes)
23% (6 votes)
Almost all
8% (2 votes)
Total votes: 26